Article

Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell Therapy

2024-01-04

Abstract excerpt

We report the 12-month follow-up results of a phase 2 clinical of Descartes-08 ( NCT04146051 ), BCMA-directed RNA chimeric antigen receptor T-cell (rCAR-T) therapy for myasthenia gravis (MG) given as an outpatient treatment without lymphodepletion. In the Phase 2a part of the study, all 7 participants who received six weekly infusions of Descartes-08 exhibited clinically meaningful improvement in common MG severi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 29384e45-5911-525c-bccf-78d5e3685b90
DOI: 10.1101/2024.01.03.24300770

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell TherapyDOI 10.1101/2024.01.03.24300770Read

Clinical characteristics and outcome of treatment-refractory myasthenia gravis -a retrospective studySemantic proximity Read

Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis Registry.Semantic proximity Read

Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized MedicineSemantic proximity Read

A Retrospective Longitudinal Cohort Study of The Clinical Burden in Myasthenia GravisSemantic proximity Read

Myasthenia gravis: from autoantibodies to therapy.Semantic proximity Read

Efgartigimod efficacy and safety in refractory Myasthenia Gravis - UK’s first real-world experienceSemantic proximity Read

Early Versus Delayed Add-on Therapy in Generalized Myasthenia Gravis: A Multicenter Real-World Cohort StudySemantic proximity Read

Spotlight on MuSK Positive Myasthenia Gravis: Clinical Characteristics, Treatment and OutcomesSemantic proximity Read

Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of its Pharmacological Profile, Clinical Utility, and Expanding ApplicationsSemantic proximity Read

Real-World Case Series of Efgartigimod for Generalized Myasthenia Gravis：Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom ControlSemantic proximity Read

Distribution and Temporal Changes of Autoantibody-Mediated Pathogenic Mechanisms Among Acetylcholine Receptor-Positive Myasthenia Gravis PatientsSemantic proximity Read

Exploring Myasthenia Gravis Subtypes: Impact on Pregnancy and Recent Treatment AdvancementsSemantic proximity Read